Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach | SpringerLink
PDF) Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
Project 1: Therapeutic Potential of Kappa Opioid Receptor Antagonists in the Treatment of Depression (Chavkin) | Conte Center
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy | ACS Chemical Neuroscience
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - ScienceDirect
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy | ACS Chemical Neuroscience
Major Depressive Disorder and Kappa Opioid Receptor
Molecules | Free Full-Text | Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities